title: Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.
authors.forename: M J
authors.initials: MJ
authors.lastname: Mozziconacci
authors.forename: S
authors.initials: S
authors.lastname: Caillères
authors.forename: C
authors.initials: C
authors.lastname: Maurice
authors.forename: N
authors.initials: N
authors.lastname: Vey
authors.forename: D
authors.initials: D
authors.lastname: Sainty
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.forename: M
authors.initials: M
authors.lastname: Lafage-Pochitaloff
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D002999:Clone Cells / Q000378:metabolism / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000473:pathology; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate